Symptoms and Disease Progression
At a Glance
CLN13 usually causes gradual changes in thinking, behavior, movement, speech, and physical function during adulthood, but the pattern and pace vary widely. Seizures may occur but are not present in everyone, and later stages may require support with swallowing and daily care.
The progression of CLN13 is a gradual process that varies significantly from one person to the next [1]. Because it is a progressive neurodegenerative disorder, symptoms worsen over time as cellular damage accumulates [1]. While the disease generally follows a trajectory of increasing cognitive and physical impairment, the specific symptoms and the speed at which they appear can differ even between siblings with the exact same genetic variant [2].
Early Signs and Initial Changes
In many cases, the first signs of CLN13 are subtle and may be easily mistaken for stress, a mood disorder, or normal early aging [3][2]. Symptoms typically emerge in adulthood, most often between the ages of 20 and 50 [2].
The early phase of the disease frequently centers on frontal/behavioral changes and cognitive decline [3][2]. This clinical pattern can look very similar to frontotemporal dementia (FTD) or early-onset Alzheimer’s disease [4]. You may notice:
- Personality Shifts: A person may become uncharacteristically impulsive, socially inappropriate, or emotionally flat (apathy) [3].
- Executive Dysfunction: Difficulty planning tasks, solving problems, or managing complex activities like finances or employment [2].
- Motor Clumsiness: Early physical signs may include minor coordination issues, a slightly unsteady walk, or subtle tremors [3][5].
Mid-Stage Progression
As the disease continues, cognitive and physical impairments become more pronounced [1]. This period is often defined by the emergence of movement disorders that significantly impact daily activities [2].
Possible mid-stage symptoms include:
- Parkinsonism: A group of movement symptoms including muscle rigidity (stiffness), slowed movements (bradykinesia), and resting tremors [3][2].
- Ataxia: A loss of full control over bodily movements, leading to a staggered gait and an increased risk of falls [1][5].
- Communication Challenges: Speech may become slurred (dysarthria), and finding the right words may become increasingly difficult [6].
- Variable Seizures: It is vital to know that seizures are not obligatory in CLN13 [2]. While some people may experience myoclonic seizures (sudden muscle jerks), others may never have a seizure at all [2][1].
Advanced Stage Features
In the advanced stages of CLN13, the person may require extensive support as the brain’s ability to control the body declines further [2][1]. It is important to recognize that not every person will experience every late-stage symptom, but preparation is key.
A characteristic advanced feature for some individuals is akinetic mutism [2]. In this state, the person is awake and their eyes may track objects, but they have a profound neurological impairment in initiating movement or speech [2]. This is not a coma, nor is it a loss of awareness, comprehension, or “will”—it is a breakdown in the brain’s motor circuits [2]. Caregivers and clinical teams should continue to look for subtle signs of communication, check for pain, and speak to the person with dignity.
Other advanced concerns can include:
- Dysphagia: Difficulty swallowing, which carries a risk of food or liquid entering the lungs (aspiration) [6].
- Severe Cognitive Decline: Extensive memory loss and diminished ability to actively communicate complex needs [2][4].
- Immobility: The person may become fully dependent on others for positioning, transfers, and daily hygiene [7].
Understanding Heterogeneity
One of the most challenging aspects of CLN13 is its heterogeneity—the fact that the disease presentation is so variable [1]. For example, in one small retrospective clinical review of 20 CLN13 patients, only 6 exhibited the “classic” symptoms historically described in medical textbooks for Kufs disease [1]. Some people have a disease course dominated by dementia, while others primarily struggle with movement issues [2][1]. Because there is no single predetermined timeline, medical care and emotional support must be individually tailored to the specific challenges the person is facing [8].
Common questions in this guide
What are the first signs of CLN13 disease?
How quickly does CLN13 progress?
Will everyone with CLN13 have seizures?
What movement problems can CLN13 cause?
What does akinetic mutism mean in advanced CLN13?
Can CLN13 cause swallowing problems?
How can families prepare for later stages of CLN13?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on the current symptoms, what stage of progression are we navigating, and what should we anticipate next?
- 2.Since seizures are possible but not always present, what specific subtle signs should I look for?
- 3.How do we distinguish between 'frontal' behavioral changes caused by the disease and other potential causes like pain or infection?
- 4.Given the risk of mobility loss, what specific mobility aids or communication tools should we be exploring now?
- 5.Can you provide a baseline assessment of swallowing function to help safely guide our nutrition plan?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (8)
- 1
Clinical Heterogeneity of Neuronal Ceroid Lipofuscinosis Type 13: A Case Report and Systematic Review of Literature.
Ghayal NB, Roemer SF, Tipton PW, et al.
Neurology. Genetics 2025; (11(1)):e200227 doi:10.1212/NXG.0000000000200227.
PMID: 39720560 - 2
Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and FTD.
van der Zee J, Mariën P, Crols R, et al.
Neurology. Genetics 2016; (2(5)):e102 doi:10.1212/NXG.0000000000000102.
PMID: 27668283 - 3
Novel frameshift CTSF mutation causing kufs disease type B mimicking frontotemporal dementia-parkinsonism.
Gultekin M, Tufekcioglu Z, Baydemir R
Neurocase 2022; (28(1)):107-109 doi:10.1080/13554794.2022.2038635.
PMID: 35139754 - 4
Exome sequencing in a consanguineous family clinically diagnosed with early-onset Alzheimer's disease identifies a homozygous CTSF mutation.
Bras J, Djaldetti R, Alves AM, et al.
Neurobiology of aging 2016; (46()):236.e1-6.
PMID: 27524508 - 5
Brain imaging in Kufs disease type B: case reports.
Di Fabio R, Colonnese C, Santorelli FM, et al.
BMC neurology 2015; (15()):102 doi:10.1186/s12883-015-0357-6.
PMID: 26141065 - 6
Management of CLN1 Disease: International Clinical Consensus.
Augustine EF, Adams HR, de Los Reyes E, et al.
Pediatric neurology 2021; (120()):38-51 doi:10.1016/j.pediatrneurol.2021.04.002.
PMID: 34000449 - 7
Management Strategies for CLN2 Disease.
Williams RE, Adams HR, Blohm M, et al.
Pediatric neurology 2017; (69()):102-112 doi:10.1016/j.pediatrneurol.2017.01.034.
PMID: 28335910 - 8
Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.
Mole SE, Schulz A, Badoe E, et al.
Orphanet journal of rare diseases 2021; (16(1)):185 doi:10.1186/s13023-021-01813-5.
PMID: 33882967
This page provides general information about CLN13 symptoms and progression and does not constitute medical advice. A neurologist or treating team can interpret an individual’s changes and recommend appropriate support.
Get notified when new evidence is published on CLN13 disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.